(Q42657080)

4 November 2017

title

Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol (English)

1 reference

4 November 2017

1 reference

multiple drug resistance

1 reference

1 reference

pulmonary tuberculosis

1 reference

R Condos

1

1 reference

4 November 2017

W N Rom

series ordinal

2

1 reference

4 November 2017

N W Schluger

series ordinal

3

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 May 1997

1 reference

4 November 2017

number of pages

3

1 reference

inferred from page(s)

published in

The Lancet

1 reference

4 November 2017

volume

349

1 reference

4 November 2017

issue

9064

1 reference

4 November 2017

page(s)

1513-1515

1 reference

Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2912273-X

7 January 2021

Outcome of MDR-TB patients, 1983-1993. Prolonged survival with appropriate therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2912273-X

7 January 2021

Drug-resistant tuberculosis in the 1990s

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2912273-X

7 January 2021

The changing face of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2912273-X

7 January 2021

Interferon-gamma in the management of infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2912273-X

7 January 2021

Recent progress in the elucidation of interferon-gamma actions: molecular biology and biological functions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2912273-X

7 January 2021

Activation of human macrophages. Comparison of other cytokines with interferon-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2912273-X

7 January 2021

Interferon-gamma and host antimicrobial defense: current and future clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2912273-X

7 January 2021

Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2912273-X

7 January 2021

Requirement for transcription factor IRF-1 in NO synthase induction in macrophages.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2912273-X

7 January 2021

Multiple defects of immune cell function in mice with disrupted interferon-gamma genes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2912273-X

7 January 2021

Immune response in mice that lack the interferon-gamma receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2912273-X

7 January 2021

Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2912273-X

7 January 2021

Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2912273-X

7 January 2021

10.1016/S0140-6736(96)12273-X

Identifiers

DOI

1 reference

4 November 2017

1 reference